X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
chemistry (312) 312
metallurgy (312) 312
organic chemistry (302) 302
human necessities (247) 247
hygiene (241) 241
medical or veterinary science (241) 241
preparations for medical, dental, or toilet purposes (229) 229
heterocyclic compounds (206) 206
specific therapeutic activity of chemical compounds ormedicinal preparations (166) 166
humans (72) 72
peptides (68) 68
microbiology (48) 48
biochemistry (47) 47
beer (45) 45
enzymology (45) 45
mutation or genetic engineering (45) 45
spirits (45) 45
vinegar (45) 45
wine (45) 45
animals (44) 44
oncology (41) 41
fermentation or enzyme-using processes to synthesise a desiredchemical compound or composition or to separate optical isomersfrom a racemic mixture (38) 38
mice (34) 34
steroids (34) 34
acyclic or carbocyclic compounds (31) 31
tumor cells, cultured (26) 26
antineoplastic agents - pharmacology (25) 25
derivatives thereof (24) 24
nucleic acids (24) 24
nucleosides (24) 24
nucleotides (24) 24
sugars (24) 24
male (23) 23
index medicus (22) 22
female (21) 21
chemical or physical processes, e.g. catalysis or colloidchemistry (20) 20
performing operations (20) 20
physical or chemical processes or apparatus in general (20) 20
their relevant apparatus (20) 20
transporting (20) 20
mice, nude (18) 18
pharmacology & pharmacy (17) 17
mice, inbred balb c (16) 16
enzyme inhibitors - pharmacology (15) 15
cancer (14) 14
compositions thereof (12) 12
culture media (12) 12
expression (12) 12
general tagging of cross-sectional technologies spanning over several sections of the ipc (12) 12
general tagging of new technological developments (12) 12
microorganisms or enzymes (12) 12
propagating, preserving or maintaining microorganisms (12) 12
technical subjects covered by former uspc cross-reference art collections [xracs] and digests (12) 12
in-vivo (11) 11
neoplasm transplantation (11) 11
physics (11) 11
processes using microorganisms (11) 11
aged (10) 10
alkaloids - pharmacology (10) 10
cell division - drug effects (10) 10
dose-response relationship, drug (10) 10
investigating or analysing materials by determining theirchemical or physical properties (10) 10
lactones - pharmacology (10) 10
measuring (10) 10
structure-activity relationship (10) 10
testing (10) 10
biochemistry & molecular biology (9) 9
breast cancer (9) 9
breast neoplasms - pathology (9) 9
cell cycle - drug effects (9) 9
macrolides (9) 9
middle aged (9) 9
adult (8) 8
antineoplastic agents - therapeutic use (8) 8
antitumor-activity (8) 8
apoptosis (8) 8
apoptosis - drug effects (8) 8
cell line, tumor (8) 8
mice, scid (8) 8
molecular structure (8) 8
technical subjects covered by former uspc (8) 8
technical subjects covered by former uspc cross-reference artcollections [xracs] and digests (8) 8
xenograft model antitumor assays (8) 8
agriculture (7) 7
animal husbandry (7) 7
antibiotics, antineoplastic - pharmacology (7) 7
breast neoplasms - drug therapy (7) 7
chemistry, medicinal (7) 7
chemotherapy (7) 7
fishing (7) 7
forestry (7) 7
hsp90 heat-shock proteins - metabolism (7) 7
hunting (7) 7
phosphorylation (7) 7
rats (7) 7
signal transduction - drug effects (7) 7
staurosporine - analogs & derivatives (7) 7
trapping (7) 7
treatment outcome (7) 7
analysis (6) 6
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (434) 434
French (140) 140
German (106) 106
Japanese (36) 36
Spanish (7) 7
Chinese (6) 6
Norwegian (6) 6
Hungarian (4) 4
Portuguese (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annals of Oncology, ISSN 0923-7534, 11/2015, Volume 26, p. vii32
Journal Article
Journal Article
Journal Article
Cancer Research, ISSN 0008-5472, 07/2018, Volume 78, Issue 13 Supplement, pp. 3959 - 3959
Journal Article
Investigational New Drugs, ISSN 0167-6997, 4/2014, Volume 32, Issue 2, pp. 355 - 361
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 2014, Volume 32, Issue 11, pp. 1157 - 1163
Journal Article
Cancer Science, ISSN 1347-9032, 04/2016, Volume 107, Issue 4, pp. 499 - 506
Numerous solid tumors overexpress or have excessively activated insulin‐like growth factor receptor‐1 (IGF‐1R). We summarize preclinical studies and the... 
insulin‐like growth factor receptor‐1 | pre‐clinical | phase I | KW‐2450 | Insulin receptor | Pre-clinical | Phase I | KW-2450 | Insulin-like growth factor receptor-1 | TARGET | EFFICACY | DUAL INHIBITOR | LINSITINIB OSI-906 | ANTITUMOR-ACTIVITY | SORAFENIB | CANCER | DISCOVERY | pre-clinical | ONCOLOGY | insulin-like growth factor receptor-1 | CARCINOMA | Colonic Neoplasms - genetics | Receptor, ErbB-2 - genetics | Colonic Neoplasms - drug therapy | Humans | Receptor, IGF Type 1 - biosynthesis | Breast Neoplasms - drug therapy | Receptor, IGF Type 1 - genetics | Xenograft Model Antitumor Assays | Protein Kinase Inhibitors - administration & dosage | Maximum Tolerated Dose | Animals | Breast Neoplasms - genetics | Signal Transduction - drug effects | Breast Neoplasms - pathology | Receptor, Insulin - genetics | Colonic Neoplasms - pathology | Receptor, Insulin - biosynthesis | Cell Line, Tumor | Adult | Female | Aged | Mice | Tyrosine | Hyperglycemia | Colon cancer | Epidermal growth factor | Analysis | Clinical trials | Phenols | Cellular signal transduction | Metastasis | Toxicity | Colorectal cancer | Nervous system | Insulin-like growth factors | Kinases | Metastases | Proteins | Signal transduction | Xenografts | Colon | Drug dosages | Protein-tyrosine kinase | Breast cancer | Insulin | Studies | Cell lines | Antitumor activity | Transduction | Solid tumors | Tumors | Index Medicus | Original
Journal Article
Therapeutic Advances in Medical Oncology, ISSN 1758-8340, 7/2018, Volume 10, pp. 1 - 14
Background: KW-2450 is an oral dual insulin-like growth factor-1 receptor/insulin receptor tyrosine kinase inhibitor. We investigated the in vitro and in vivo... 
letrozole | lapatinib | breast cancer | estrogen receptor-positive | KW-2450 | HER2-positive | CELLS | HUMAN-BREAST-CANCER | TRASTUZUMAB | MECHANISM | RECEPTOR | ONCOGENE | THERAPY | ONCOLOGY | RESISTANCE | EXPRESSION | GROWTH-FACTOR-I
Journal Article
British Journal of Haematology, ISSN 0007-1048, 06/2015, Volume 169, Issue 5, pp. 672 - 682
Summary This multicentre, randomized, phase II study was conducted to examine whether the addition of mogamulizumab, a humanized anti‐CC chemokine receptor 4... 
mogamulizumab | randomized phase II study | CCR4 | adult T‐cell leukaemia‐lymphoma | antibody therapy | Adult T-cell leukaemia-lymphoma | Mogamulizumab | Antibody therapy | Randomized phase II study | adult T-cell leukaemia-lymphoma | MONOCLONAL-ANTIBODY KW-0761 | RECEPTOR | LEUKEMIA/LYMPHOMA | HEMATOLOGY | EXPRESSION | ASSOCIATION | TRANSPLANTATION | Doxorubicin - therapeutic use | Nitrosourea Compounds - adverse effects | Prednisolone - adverse effects | Nitrosourea Compounds - therapeutic use | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Carboplatin - adverse effects | Antibodies, Monoclonal, Humanized - administration & dosage | Leukemia-Lymphoma, Adult T-Cell - drug therapy | Carboplatin - therapeutic use | Vindesine - adverse effects | Vindesine - therapeutic use | Aged, 80 and over | Adult | Female | Prednisolone - therapeutic use | Etoposide - adverse effects | Leukemia-Lymphoma, Adult T-Cell - mortality | Etoposide - therapeutic use | Treatment Outcome | Leukemia-Lymphoma, Adult T-Cell - pathology | Disease Progression | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - therapeutic use | Vincristine - adverse effects | Aged | Doxorubicin - adverse effects | Chemotherapy | Lymphomas | T cells | Leukemia | Cancer | Haematological Malignancy | Research Paper
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 7/2014, Volume 74, Issue 1, pp. 15 - 23
Eg5, a mitotic motor kinesin protein, plays an essential role in bipolar spindle formation in the M phase of the cell cycle. LY2523355 (litronesib) is an... 
Solid tumor | Eg5 inhibitor | Medicine & Public Health | Litronesib | LY2523355 | Oncology | Cancer Research | Phase 1 study | Pharmacology/Toxicology | TARGET | ISPINESIB | CANCER | DOCETAXEL | AZD4877 | RESISTANT | PHARMACOKINETICS | ONCOLOGY | I TRIAL | PHARMACOLOGY & PHARMACY | SPINDLE PROTEIN INHIBITOR | ESCALATION | Neoplasms - metabolism | Drugs, Investigational - adverse effects | Allosteric Regulation | Humans | Middle Aged | Drugs, Investigational - pharmacokinetics | Drugs, Investigational - therapeutic use | Half-Life | Male | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Neoplasm Proteins - metabolism | Dose-Response Relationship, Drug | Enzyme Inhibitors - administration & dosage | Thiadiazoles - adverse effects | Chemotherapy-Induced Febrile Neutropenia - physiopathology | Neoplasms - blood | Enzyme Inhibitors - pharmacokinetics | Antineoplastic Agents - adverse effects | Thiadiazoles - therapeutic use | Colorectal Neoplasms - drug therapy | Leukopenia - chemically induced | Adult | Female | Antineoplastic Agents - pharmacokinetics | Kinesin - antagonists & inhibitors | Colorectal Neoplasms - metabolism | Enzyme Inhibitors - adverse effects | Severity of Illness Index | Colorectal Neoplasms - blood | Japan | Leukopenia - physiopathology | Cancer Care Facilities | Enzyme Inhibitors - therapeutic use | Sulfonamides - pharmacokinetics | Kinesin - metabolism | Neoplasms - drug therapy | Sulfonamides - therapeutic use | Drugs, Investigational - administration & dosage | Sulfonamides - adverse effects | Thiadiazoles - pharmacokinetics | Aged | Sulfonamides - administration & dosage | Thiadiazoles - administration & dosage | Medicine, Experimental | Medical research | Macrophage colony stimulating factor | Granulocyte colony-stimulating factor | Analysis | Tumors | Index Medicus
Journal Article